Lupin acquires Dutch injectable company Nanomi BV

Lupin, India's second-largest pharmaceutical company by market value, yesterday struck a deal to acquire Netherlands-based injectable company Nanomi BV.

The Mumbai-based company did not disclose the financial terms of the deal, but said that the acquisition will allow it to enter into the technology-intensive injectables space.

Commenting  on the  acquisition Vinita Gupta, CEO of Lupin said,  ''We are very pleased with the acquisition of Nanomi. With the use of Nanomi's proprietary technology platform, Lupin would be able to make significant in-roads into the niche area of complex injectables.''

Founded in 2004 as an independent spin-off from the University of Twente, Nanomi is an independent, privately-owned drug delivery company that develops pharmaceutical products based on nano-and microparticles.

Nanomi has been profitable since its inception and has successfully entered into business agreements for the development of products for several pharma and biotech companies.

Nanomi's core technology is its proprietary microsieve emulsification process. The microsieves are made by precise semi-conductor technology, which enables the production of highly monodisperse droplets and particles in a robust, reproducible and cost effective way.

Its key application areas are drug delivery and controlled release, diagnostics, molecular imaging and research & analysis.

Nanomi develops its proprietary technology platform and enters into partnerships with companies that have a high value product/application. Return on investments comes from royalty payments and technology transfer, which is based on product added value.

Nanomi is solely involved in business-to-business partnerships and does not distribute and market products on its own.